MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”AL amyloidosis, MPEApril 24, 2024
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, MyelomaApril 18, 2024
MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPEApril 8, 2024
Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”AL amyloidosis, MPEMarch 27, 2024
Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, MyelomaMarch 25, 2024
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, MyelomaMarch 8, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024